Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

13.2%

5 terminated/withdrawn out of 38 trials

Success Rate

79.2%

-7.3% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

5%

1 of 19 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
35(92.1%)
Phase 2
3(7.9%)
38Total
Phase 1(35)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials
NCT01069653Phase 1Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer

Role: collaborator

NCT01069640Phase 1Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

Role: collaborator

NCT01069575Phase 1Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer

Role: collaborator

NCT00624182Phase 1Suspended

Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer

Role: collaborator

NCT00641615Phase 1Completed

Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer

Role: collaborator

NCT00874588Phase 1Completed

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

Role: collaborator

NCT00633724Phase 1Completed

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

Role: collaborator

NCT00655785Phase 1Completed

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)

Role: collaborator

NCT00639925Phase 1Unknown

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer

Role: collaborator

NCT00791570Phase 1Completed

Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy

Role: collaborator

NCT00845611Phase 1Completed

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Role: collaborator

NCT00753844Phase 1Completed

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer

Role: collaborator

NCT00683085Phase 1Terminated

Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Role: collaborator

NCT00632333Phase 1Unknown

Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

Role: collaborator

NCT00676949Phase 1Completed

Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors

Role: collaborator

NCT01225471Phase 1Unknown

Novel Peptide Vaccination for Patients With Advanced Prostate Cancer

Role: collaborator

NCT00633204Phase 2Unknown

Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer

Role: collaborator

NCT01267578Phase 2Unknown

Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)

Role: collaborator

NCT01266707Phase 1Unknown

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Role: collaborator

NCT01266720Phase 1Unknown

HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Role: collaborator